-The Hindu Medicines remain overpriced and unaffordable in India. In a country mired in poverty, medical debt remains the second biggest factor for keeping millions in poverty. The international pharmaceutical industry has found its cash cow in India’s beleaguered consumers. With a minimum wage of Rs.250/day for a government worker, a basic wage worker afflicted with a chronic disease like multi-drug-resistant tuberculosis faces penury. His treatment, with drug combinations, which works out...
More »SEARCH RESULT
Total Matching Records found : 378
In 10 yrs, govt aims 25% cut in premature cancer deaths -Sushmi Dey
-The Times of India NEW DELHI: The health ministry has chalked out an overarching National Multi-Sectoral Action Plan with the aim to reduce premature deaths from cancer, diabetes and heart diseases by 25% in the next 10 years (by 2025). The plan, which includes initiatives and measures from at least 27 government departments including ministries like environment, women and child development, urban development, industries etc, is in the final stage and...
More »Govt to sell 439 key drugs at low prices -Sushmi Dey
-The Times of India NEW DELHI: The government is set to expand the coverage of its Jan Aushadhi scheme. It will offer 439 life-saving medicines, including cancer and cardiovascular drugs, as well as 250 medical devices like stents and implants at 40-50% discounted prices. The department of pharmaceuticals plans to open 300 Jan Aushadhi stores across the country by March and another 3,000 by 2017. Presently, only 45 medicines are available in...
More »Rural India too battles hypertension -Roli Srivastava & Rukmini S
-The Hindu Obesity and diabetes cases increase in urban areas; experts blame it on stress and faulty diet. Higher stress levels in rural India and faulty diet in cities have thrown up two most disturbing health concerns in the National Family Health Survey (NFHS), the data for which was released on Wednesday. While obesity levels have shot up in the country since the last NFHS survey in 2005-06, the number of people...
More »New diabetes drug cuts cost by 80%
-The Times of India MUMBAI: Diabetics in the country have something to cheer about. A completely new drug in the 'gliptin' family has disrupted the anti-diabetes market by lowering the cost of therapy for patients by 80%. With the launch of the teneligliptin molecule, the popular gliptin category has witnessed a price erosion of over 80% in the last six months, bringing down the cost for a day's treatment from Rs...
More »
